Abstract. Genistein, 5,7,4'-trihydroxylisoflavone, a major component of soybean products, has been reported to possess anticancer activities. We examined the antitumor effects of 7-difluoromethoxyl-5,4'-di-n-octylgenistein (DFOG), a novel synthetic genistein derivative, on human ovarian cancer cells as well as the molecular mechanism. The growth-inhibitory effects of genistein and DFOG were determined using MTT assay and clonogenic assay in CoC1 and SKOV3 human ovarian cancer cells. Apoptotic activities of DFOG were observed using histone/DNA ELISA assay and flow cytometry with propidium iodide (PI) staining. Multiple molecular techniques, such as RT-PCR, western blot analysis, siRNA and cDNA transfection were used to explore the molecular mechanism. We demonstrated that nine of the genistein derivatives had a more effective antitumor activity than genistein. Among the afore-mentioned derivatives, DFOG presented with the strongest activity against CoC1 and SKOV3 cells in vitro. DFOG and genistein inhibited the growth of CoC1 and SKOV3 cells, accompanied by cell cycle arrest in the G2/M phase. DFOG caused apoptotic cell death with concomitant attenuation of Forkhead box protein M1 (FoxM1) and its downstream genes, such as survivin, CDC25B, cyclin B, and increased p27 KIP1 . Downregulation of FoxM1 by siRNA followed by DFOG treatment resulted in enhanced cell growth inhibition and induction of apoptosis. Upregulation of FoxM1 by cDNA transfection attenuated DFOG-induced cell growth inhibition and apoptotic cell death. Our results show that the molecular role of FoxM1 in mediating the biological effects of DFOG and genistein in human ovarian cancer cells suggests that FoxM1 could be a novel target for the treatment of human ovarian cancer.
Introduction
Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer death (1) . This high mortality rate is associated with difficulties in diagnosis of the early stages of the disease and because of a high rate of recurrence (2, 3) . Although 80% of cancers initially respond to chemotherapy, the majority ultimately reoccurs with less than 15% remaining in remission (4) . Therefore, the need for a new drug for the prevention and treatment of ovarian cancer is urgent.
Genistein (5,7,4'-trihydroxyisoflavone) is an isoflavone found in soy products that has been shown to affect the cell cycle progression and apoptosis in various cancer cell lines (5, 6) . The low absorption of genistein in the intestine and the rapid metabolic elimination resulting from the hydroxyls at the C-5, C-7, and C-4' positions allows genistein to bind to glucuronic and sulfuric acid, and reduce its bioavailability and bioactivity in vivo (7) , thus restricting its clinical application. Recently, we synthesized a series of difluoromethoxylated genistein derivatives and determined their protective effects against vascular endothelial cells (8) . There are only a few studies reported on the anticancer effects of fluorinated genistein derivatives.
EOC has been shown to have an activated Forkhead box protein M1 (FoxM1) signaling pathway (9) . The FoxM1 belongs to a family of evolutionary conserved transcriptional regulators that are characterized by the presence of a DNA-binding domain called the Forkhead box domain (10) . Many studies have shown that FoxM1 signaling plays important roles in cellular developmental pathways, and thus, activation of FoxM1 signaling has been reported to be associated with carcinogenesis (11) . FoxM1 signaling is frequently upregulated in cancers, including lung, breast, pancreatic and ovarian cancer (9, (12) (13) (14) . Moreover, FoxM1 has been shown to regulate the transcription of cell cycle genes, including CDC25B, cyclin B, and p27
KIP1
, and apoptosis-relative genes, such as survivin (10, 15) . Studies by Wang et al have shown that genistein may inhibit FoxM1 activation in pancreatic cancer cells, leading to apoptotic cell death (16) . Accordingly, we hypothesized that that genistein and the novel synthetic genistein derivative DFOG (7-difluoromethoxyl-5,4'-di-noctylgenistein) may target the inactivation of FoxM1, which could represent a promising strategy for ovarian cancer therapy. The First Affiliated Hospital of Guangzhou Medical College, Guangzhou 510120;
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In this study, we investigated whether DFOG and genistein inhibit the growth of ovarian cancer cells and could be attributed to the inhibition of FoxM1 expression. We found that DFOG and genistein downregulated the FoxM1 expression and its downstream genes, including survivin, CDC25B, and cyclin B, and increased p27 KIP1 , resulting in the induction of growth inhibition and apoptosis in ovarian cancer cells. These results provide supportive evidence for the first time that FoxM1 is a legitimate target in ovarian cancer and that the targeted inactivation of FoxM1, especially by the novel synthetic derivative of genistein, DGOG and genistein as shown here, would be highly relevant for designing novel strategies for the prevention of tumor progression and/or treatment of ovarian cancer.
Materials and methods
Cell culture and experimental reagents. The human ovarian cancer cell lines CoC1 and SKOV3 were purchased from the China Centre for Type Culture Collection (CCTCC; Wuhan, China) and were maintained in DMEM medium (Invitrogen Corp., Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 4 mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin, and incubated at 37˚C in a humidified atmosphere of 5% CO 2 . The difluoromethoxylated genistein derivatives 2,4a-4h were prepared via the afore-mentioned method (8) (Table I) . Primary antibodies for FoxM1, survivin, cyclin B, p27 KIP1 , CDC25B, and β-actin, as well as horseradish peroxidase-conjugated rabbit anti-mouse secondary antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Lipofectamine 2000 was purchased from Invitrogen. Protease inhibitor cocktail, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and all other chemicals were obtained from Sigma-Aldrich, St. Louis, MO, USA. Genistein and the difluoromethoxylated genistein derivatives were dissolved in dimethyl sulfoxide (DMSO) to make a 10 mM stock solution and were added directly to the media at different concentrations.
MTT assay. Cells were seeded in a 96-well plate at a density of 5,000 cells/well as previously described (17) . After incubation for 24 h, different concentrations of genistein and genistein derivatives (0.1, 0.3, 1.0, 3.0, 10.0 and 30.0 µmol/l) were added to each well and cultured for 48 h. The medium was removed and then incubated with 5 mg/l MTT for 4 h. Next, the supernatant was removed after centrifugation. Finally, 100 µl of DMSO was added and an absorbance at 570 nm wavelength (A 570 ) was measured by means of an Enzyme-Labeling Instrument (ELX-800 type; BioTek, Shanghai, China). Relative cell proliferation inhibition rate (IR) = (1-average A 570 of the experimental group/average A 570 of the control group) x 100%. The IC 50 (defined as the drug concentration, of which 50% cell viability was inhibited) was assessed from the dose-response curves using GraphPad Prism program (version 4; GraphPad Software, Inc., La Jolla, CA, USA).
Clonogenic assay. Cells were plated in 24-well plates at a density of 300 cells/well for 24 h prior to the addition of various concentrations of DFOG (1, 5 and 10 µmol/l) and 10 µmol/l genistein. After 48 h of treatment, the drugcontaining medium was removed and replaced with complete growth medium. Medium was changed every 3 days for 7 to 10 days until visible colonies formed. Colonies were simultaneously fixed and stained with Wright-Giemsa solution in methanol and manually counted. Individual stained colonies in each well were counted and the colony formation fraction was calculated as follows: colony number/(number of cells seeded x plating efficiency), where plating efficiency is equivalent to the colony number divided by the number of cells seeded in the drug-free medium. FCM analysis using propidium iodide staining. Cells were seeded at a density of 4x10 6 cells/well in 100-ml culture flasks for 24 h and then treated with the medium containing various concentrations of the testing agents and 10% fetal bovine serum for 24 h. Propidium iodide (PI) staining for DNA content analysis was performed as previously described (18) .
Histone/DNA ELISA for detecting apoptosis. The cell apoptosis ELISA detection kit was used to detect apoptosis in cells treated with DFOG and genistein according to the manufacturer's protocol. Briefly, cells were seeded in a 96-well plate at a density of 1x10 4 cells/well for 24 h, and the testing agents were then added to the culture medium containing 10% fetal bovine serum. After 48 h, we transferred the cytoplasm of the control and treatment groups to the 96-well plate pre-coated with streptavidin that had been previously incubated with the biotinylated histone antibody and peroxidase-tagged mouse anti-human DNA for 2 h at room temperature. The absorbance was measured at 405 nm with the EXL-800-type enzymelinked immunosorbent apparatus.
Reverse transcription-PCR. Total RNA was extracted using TRIzol reagent (Life Technologies, Inc., Gaithersburg, MD, USA). The integrity of the RNA was checked by 2% agarose gel electrophoresis. Approximately 2 µg RNA was reversetranscribed following the protocol of the Super Script™ First-Strand Synthesis System (Invitrogen Corp., Carlsbad, CA, USA). CDNAs encoding FoxM1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes were amplified by PCR as follows: denaturation at 94˚C for 30 sec, annealing at 63˚C for 30 sec, and elongation at 72˚C for 45 sec. Primer sequence was performed in accordance with Wang et al (19) . For FoxM1, the forward primer was (5'-AACCGCTACTTG ACATTGG-3') and reverse primer was (5'-GCAGTGGCTT CATCTTCC-3'). A housekeeping gene, GAPDH, was used as the internal control. The forward primer was 5'-ACCCAGAA GACTGTGGATGG-3' , and the reverse primer was 5'-TGCTGT AGCCAAATTCGTTG-3'. PCR products were analyzed by agarose (2%) gel electrophoresis, and the amplicon size for FoxM1 was 358 bp, and for GAPDH it was 473 bp.
Plasmids and transfections. FoxM1 siRNA and siRNA controls were obtained from Santa Cruz Biotechnology. The FoxM1 cDNA plasmid was purchased from OriGene Technologies Inc. (Rockville, MD, USA). Human ovarian cancer SKOV3 cells were transfected with FoxM1, siRNA, and cDNA, respectively, using Lipofectamine 2000 (Invitrogen) as described by Wang et al (19) .
Western blot analysis. Western blot analysis was carried out as previously described (18) . Anti-FoxM1, anti-cyclin B, anti-p27 KIP1 , anti-CDC25B, anti-survivin, and anti-β-actin were used as primary antibodies. Cells were lysed in a lysis buffer by incubating for 20 min at 4˚C. The protein concentration was determined by using the Bio-Rad assay system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Total proteins were fractionated using SDS-PAGE and transferred onto Polyvinylidene fluoride membrane (PVDF) (Millipore, Billerica, MA, USA). The signals were detected using an ECL Advance Western Blotting Analysis System (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA).
Statistical analysis. The database was set up with the SPSS 15.0 software package (SPSS Inc., Chicago, IL, USA) for analysis. Data are presented as the mean ± SD. The means of multiple groups were compared with one-way ANOVA, after the equal check of variance, and the comparisons among the means were performed using the LSD method. Statistical comparison was also performed with two-tailed t-test when appropriate. P<0.05 was considered as statistically significant.
Results
Effects of genistein and genistein derivatives on cell growth inhibition and cycle arrest of ovarian cancer cells. First, we examined the effect of genistein and the genistein derivatives on cell viability of SKOV3 and CoC1 cells using MTT assay. Nine of difluoromethylated genistein derivatives had more effective antitumor activities than genistein. Among the derivatives tested, DFOG showed the strongest activity against SKOV3 and CoC1 in vitro (Fig. 1A and B) . IC 50 of DFOG treated for 48 h was 5.6±1.3 µmol/l for SKOV3 cells and 5.3±1.2 µmol/l for CoC1 cells. Furthermore, the potency of DFOG was 8.6 and 9.7 times than that of the lead compound, genistein (GEN, IC 50 was 48.2±4.6 µmol/l for SKOV3 cells and 51.4 l±3.6 µmol/l for CoC1 cells).
In order to confirm our results, we tested the effects of DFOG on cell growth by clonogenic assay. Fig. 1C and D show that DFOG treatment resulted in a significant inhibition of colony formation of SKOV3 cells when compared to control. Overall, the results from clonogenic assay was consistent with the MTT data as shown in Fig. 1A , suggesting that DFOG inhibits the growth of ovarian cancer cells.
Additionally, to assess whether the loss of cell viability could in part be due to the induction of cell cycle arrest, we evaluated the effects of DFOG treatment on the distribution in the cell phase using FCM after PI staining. As shown in Fig. 1E and F, in the ovarian cancer SKOV3 cell line, DFOG treatment caused a significant accumulation of cells in the G2/M phase and a marked decrease in the G1/G0 phase when compared with control cells. The similar results were observed in CoC1 cells (data not shown). These results provided convincing data by showing that the novel synthetic genistein analogue DFOG induced the growth inhibition and arrest of cell cycle in G2/M phase in ovarian cancer cells.
Effect of DFOG on apoptosis in ovarian cancer cells.
To assess whether the loss of cell viability could in part be due to the induction of apoptosis, we next examined the effects of DFOG and genistein on apoptosis in CoC1 and SKOV3 cells using different approaches. After 48 h of exposure, DFOG significantly induced histone/DNA fragmentation in a concentration-dependent manner ( Fig. 2A and B) . Fig. 2C and D show that DFOG treatment resulted in a dose-dependent increase of the Sub-G1 population in SKOV3 cells (P<0.05). Similar results were observed in CoC1 cells (data not shown). Taken together, our results provided convincing data demonstrating that DFOG and genistein were able to induce apoptosis in ovarian cancer cells. (16), we investigated whether DFOG could regulate FoxM1 signaling pathways using molecular and mechanistic approaches. The expression of FoxM1 was determined using RT-PCR and western blot analysis, respectively. The results showed that FoxM1 was overexpressed in SKOV3 ( Fig. 3A and B) and CoC1 ( Fig. 3C and D) cell lines. We found that FoxM1 was downregulated by DFOG in SKOV3 (Fig. 3A and B) and CoC1 ( Fig. 3C and D . To determine the expression of these proteins, we used western blot analysis. We found that DFOG inhibited the expression of CDC25B, cyclin B, and survivin, and increased p27 KIP1 at the protein levels in SKOV3 (Fig. 4A) and CoC1 (Fig. 4B) cells.
Effect of downregulation of FoxM1 expression by siRNA on DFOG-induced growth inhibition and apoptosis in SKOV3
cells. Downregulation of FoxM1 by siRNA transfection showed less expression of FoxM1 protein in SKOV3 cells, as confirmed by western blotting (Fig. 5A) . Furthermore, we found that the downregulation of FoxM1 expression by DFOG significantly inhibited cell viability (Fig. 5B ) and induced apoptotic cell death in SKOV3 (Fig. 5C and D) . In addition, DFOG plus FoxM1 siRNA inhibited cell growth and induced apoptosis to a greater degree compared with DFOG alone (Fig. 5B-D) . These results provide some molecular evidence suggesting the DFOG-induced inhibition of the growth and apoptosis is mediated via the inactivation of FoxM1 in ovarian cancer cells.
Effects of overexpression of FoxM1 by cDNA transfection on DFOG-induced cell growth inhibition in SKOV3 cells.
Upregulation of FoxM1 by cDNA transfection showed an overexpression of FoxM1 protein in SKOV3 cells, as confirmed by western blotting (Fig. 6A) . The results showed that overexpression of FoxM1 rescued DFOG-induced cell viability inhibition to a certain degree (Fig. 6B ) and apoptotic cell death (Fig. 6C  and D) . These results provide mechanistic evidence suggesting that the DFOG inhibited cell growth is in part due to the inactivation of FoxM1 signaling pathway in ovarian cancer cells.
Discussion
A variety of studies have shown overexpression of FoxM1 gene in human cancer cells and tissues, including ovarian cancer (9, (11) (12) (13) (14) (19) (20) (21) (22) , and this emerging evidence suggests that the inactivation of FoxM1 may play an important role in cancer therapy. For example, FoxM1 could be downregulated by some drugs, such as siomycin A, thiostrepton, and EGFR inhibitor gefitinib (22) (23) (24) Many studies showed that FoxM1 promotes cell growth and stimulates the expression of genes critical for the G1/S transition, S-phase progression, the G2/M transition, and M-phase progression (28) (29) (30) . Because downregulation of FoxM1 by DFOG or genistein reduced cell growth, we investigated whether cell growth inhibition was due to cell cycle arrest in any specific phase of the cell cycle. We found that treatment with DFOG or genistein increased cell population in the G2/M phase and decreased cells in the G1 and S phase. Diminished cell population of cells in G1 and S phase and growth rate was associated with increased expression of the CdkI protein p27 KIP1 , which is known to have negative effects on cell cycle machinery by binding to various cyclin-Cdk complexes and inhibiting their activities (28, 29) . FoxM1 includes CDC25B phosphatase, which is important for the activation of Cdk1, and a number of the genes encoding proteins essential for the correct execution of mitosis such as Plk1 kinase, AurkB, CENPB, and survivin (30) . We observed a marked reduction of CDC25B and cyclin B expression in cells treated with DFOG and genistein. In our study, the decrease in CDC25, cyclin B, and the increased expression of p27 KIP1 were strongly correlated with the altered cell cycle distribution phenotype and growth suppression. These results suggest that DFOG and genistein affects the ovarian cancer cell cycle by regulating the expression levels of CDC25B, cyclin B, and CDK inhibitors p27 KIP1 through downregulation of FoxM1 expression. In addition, survivin, an inhibitor of apoptosis and a key regulator of mitosis, is upregulated in a variety of cancer cells and is often associated with a worse prognosis (31) . Notably, several studies have shown that FoxM1 can regulate survivin expression (32, 33) . Therefore, we examined the effects of DFOG and genistein on apoptosis and the expression of FoxM1 and its downstream target, survivin. Our results show that DFOG and genistein efficaciously induced apoptotic cell death of ovarian cancer cells. Furthermore, DFOG and genistein inhibited the expression of FoxM1 and survivin. Therefore, DFOG and genistein-induced apoptotic cell death could be partly mediated via the inactivation of FoxM1 activity. We found that the downregulation of FoxM1 by siRNA together with either DFOG or genistein treatment induced apoptosis to a greater degree in ovarian cancer cells when compared to DFOG or genistein treatment alone. In view of these findings, we strongly believe that the inactivation of FoxM1 by DFOG and genistein results in the downregulation of its target genes, which are believed to be mechanistically linked with inhibition of cell growth and induction of apoptosis by treatment with DFOG or genistein.
In summary, we presented experimental evidence that strongly supports the role of DFOG, a novel genistein derivative, as an antitumor agent mediated through inactivation of FoxM1 signaling pathway. Further in depth investigations are necessary in order to identify how DFOG could regulate the FoxM1 pathway, and further studies are also warranted to assess the antitumor activity mediated by the inactivation of FoxM1 by either genistein, DFOG, or other synthetic compounds in preclinical animal models for the successful treatment of ovarian cancer. It is also tempting to speculate that the inactivation of FoxM1 together with the treatment of ovarian cancer cells with conventional agents could be a useful strategy toward better treatment.
